<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00368966</url>
  </required_header>
  <id_info>
    <org_study_id>6096A1-501</org_study_id>
    <nct_id>NCT00368966</nct_id>
  </id_info>
  <brief_title>Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.</brief_title>
  <official_title>A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and immunogenicity of a
      13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given
      concomitantly with routine pediatric vaccinations in Spain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Predefined Meningococcal C Serum Bactericidal Assay (SBA) Titer of ≥ 1:8, and a Predefined Antibody Level for Diphtheria in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series</measure>
    <time_frame>One month after 2-doses of the infant series (5 months of age)</time_frame>
    <description>Percentage of participants achieving predefined antibody threshold levels; greater than or equal to (≥) 1:8 for meningococcal C SBA titer and ≥ 0.10 or &gt;=0.01 International Units Per Milliliter (IU/mL) for diphtheria along with the corresponding 95% Confidence Interval (CI) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of Meningococcal C in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series</measure>
    <time_frame>One month after 2-doses of the infant series (5 months of age)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentration (GMC) for Diphtheria in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series</measure>
    <time_frame>One month after 2-doses of the infant series (5 months of age)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Local Reactions</measure>
    <time_frame>During the 4-day period after each dose</time_frame>
    <description>Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig) (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Systemic Events</measure>
    <time_frame>During the 4-day period after each dose</time_frame>
    <description>Systemic events (fever [Fv] ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased [Decr] appetite, irritability, increased [Incr] sleep, decreased sleep, hives, use of medication [Med] to treat symptoms [sx], and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Group After the Second Dose and After the Third Dose of a 3-Dose Infant Series and After the Toddler Dose</measure>
    <time_frame>One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)</time_frame>
    <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes which are present in both 7vPnC and 13vPnC (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Predefined Antibody Levels for Pertussis, Diphtheria, Tetanus, and Poliovirus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose</measure>
    <time_frame>One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)</time_frame>
    <description>Percentage of participants achieving predefined antibody threshold levels with the corresponding 95% CI for each concomitant antigen (pertussis antigens including Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA), and Pertactin (PRN); diphtheria; tetanus; and poliovirus types 1, 2, and 3) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMT) for Poliovirus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose</measure>
    <time_frame>One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentrations (GMC) for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose</measure>
    <time_frame>One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentrations (GMC) for Pertussis in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose</measure>
    <time_frame>One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)</time_frame>
    <description>GMCs with the corresponding 95% CI for each concomitant antigen pertussis antigens (PT, FHA, PRN, and FIM) as measured by EU/mL are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Antibody Level ≥ 0.35 Microgram Per Milliliter (μg/mL) in 13vPnC Group After the Second Dose and After the Third Dose of a 3-Dose Infant Series and After the Toddler Dose</measure>
    <time_frame>One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)</time_frame>
    <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes, present in both 13vPnC and 7vPnC (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">619</enrollment>
  <condition>Vaccines, Pneumococcal</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent Pneumococcal Conjugate Vaccine</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>7-valent Pneumococcal Conjugate Vaccine</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy 2-month-old infants

          -  Available for the entire study period

        Exclusion criteria:

          -  Previous vaccination with any vaccine before the start of the study

          -  Known contraindication to vaccination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>98 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Spain, infomed@wyeth.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Ferrol</city>
        <state>A Coruna</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Argentona</city>
        <state>Barcelona</state>
        <zip>08310</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sant Adria de Besos</city>
        <state>Barcelona</state>
        <zip>08930</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sant Cugat del Valles</city>
        <state>Barcelona</state>
        <zip>08195</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sant Cugat del Valles</city>
        <state>Barcelona</state>
        <zip>08197</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bilbao</city>
        <state>Bizkaia</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burela</city>
        <state>Lugo</state>
        <zip>27880</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28943</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <zip>28900</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <zip>28902</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mostoles</city>
        <state>Madrid</state>
        <zip>28937</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parla</city>
        <state>Madrid</state>
        <zip>28980</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antequera</city>
        <state>Malaga</state>
        <zip>29200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burjassot</city>
        <state>Valencia</state>
        <zip>46110</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Eliana</city>
        <state>Valencia</state>
        <zip>46183</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quart de Poblet</city>
        <state>Valencia</state>
        <zip>46930</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almeria</city>
        <zip>04007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almeria</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almeria</city>
        <zip>04120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Coruna</city>
        <zip>15270</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malaga</city>
        <zip>29015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ourense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46024</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2006</study_first_submitted>
  <study_first_submitted_qc>August 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <results_first_submitted>March 26, 2010</results_first_submitted>
  <results_first_submitted_qc>July 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 16, 2012</results_first_posted>
  <disposition_first_submitted>February 26, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 28, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 30, 2009</disposition_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumococcal</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Vaccine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited in Spain from October 2006 to December 2006.</recruitment_details>
      <pre_assignment_details>Participants were enrolled into the study according to inclusion/exclusion criteria without a screening period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>13vPnC</title>
          <description>Participants received one single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with a combination vaccine diphtheria, tetanus, and pertussis (acellular) vaccine (DTPa), hepatitis B virus vaccine (HBV), inactivated poliovirus (IPV), and hemophilus influenza type b (Hib) vaccine (Infanrix hexa) and a meningococcal C conjugate vaccine (Meningitec) at 2 and 4 months. Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months. Participants received one single 0.5 mL dose of 13vPnC coadministered with a combination vaccine measles, mumps, rubella live virus (MMR II) at 12 months. Participants received one single 0.5 mL dose of 13vPnC coadministered with DTPa, IPV, and Hib vaccine (Infanrix-IPV+Hib) and Meningitec at 15 months.</description>
        </group>
        <group group_id="P2">
          <title>7vPnC</title>
          <description>Participants received one single 0.5 milliliter (mL) dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with a combination vaccine diphtheria, tetanus, and pertussis (acellular) vaccine (DTPa), hepatitis B virus vaccine (HBV), inactivated poliovirus (IPV), and hemophilus influenza type b (Hib) vaccine (Infanrix hexa) and a meningococcal C conjugate vaccine (Meningitec) at 2 and 4 months. Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 6 months. Participants received one single 0.5 mL dose of 7vPnC coadministered with a combination vaccine measles, mumps, rubella live virus (MMR II) at 12 months. Participants received one single 0.5 mL dose of 7vPnC coadministered with DTPa, IPV, and Hib vaccine (Infanrix-IPV+Hib) and Meningitec at 15 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="315"/>
                <participants group_id="P2" count="304"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="314"/>
                <participants group_id="P2" count="302">1 randomized to 7vPnC but given 13vPnC vaccine; 1 was withdrawn before receiving 7vPnC vaccine</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="307">1 randomized but incorrectly given 7vPnC</participants>
                <participants group_id="P2" count="298"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="301"/>
                <participants group_id="P2" count="296">1 randomized but incorrectly given 13vPnC</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="299"/>
                <participants group_id="P2" count="294"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomization error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to meet eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Infant</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="299"/>
                <participants group_id="P2" count="294"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="293"/>
                <participants group_id="P2" count="289"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Toddler Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="293"/>
                <participants group_id="P2" count="289"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="292"/>
                <participants group_id="P2" count="286"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC</title>
          <description>Subjects received 1 dose (0.5 mL) of 13vPnC together with 1 dose (0.5 mL) of each of the following concomitant vaccines: Infanrix hexa and Meningitec at 2 and 4 months. At 6 months subjects received 13vPnC and Infanrix hexa. At 12 months subjects received MMR II. At 15 months subjects received 13vPnC and Infanrix-IPV+Hib, Meningitec.</description>
        </group>
        <group group_id="B2">
          <title>7vPnC</title>
          <description>Subjects received 1 dose (0.5 mL) of 7vPnC together with 1 dose (0.5 mL) of each of the following concomitant vaccines: Infanrix hexa and Meningitec at 2 and 4 months. At 6 months subjects received 7vPnC and Infanrix hexa. At 12 months subjects received MMR II. At 15 months subjects received 7vPnC and Infanrix-IPV+Hib, Meningitec.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="315"/>
            <count group_id="B2" value="304"/>
            <count group_id="B3" value="619"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.1" spread="0.5"/>
                    <measurement group_id="B2" value="2.1" spread="0.5"/>
                    <measurement group_id="B3" value="2.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Predefined Meningococcal C Serum Bactericidal Assay (SBA) Titer of ≥ 1:8, and a Predefined Antibody Level for Diphtheria in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series</title>
        <description>Percentage of participants achieving predefined antibody threshold levels; greater than or equal to (≥) 1:8 for meningococcal C SBA titer and ≥ 0.10 or &gt;=0.01 International Units Per Milliliter (IU/mL) for diphtheria along with the corresponding 95% Confidence Interval (CI) are presented.</description>
        <time_frame>One month after 2-doses of the infant series (5 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 and 4 months. Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months (infant series). Participants received one single 0.5 mL dose of 13vPnC coadministered with MMR II at 12 months. Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 and 4 months. Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 6 months (infant series). Participants received one single 0.5 mL dose of 7vPnC coadministered with MMR II at 12 months. Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Predefined Meningococcal C Serum Bactericidal Assay (SBA) Titer of ≥ 1:8, and a Predefined Antibody Level for Diphtheria in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series</title>
          <description>Percentage of participants achieving predefined antibody threshold levels; greater than or equal to (≥) 1:8 for meningococcal C SBA titer and ≥ 0.10 or &gt;=0.01 International Units Per Milliliter (IU/mL) for diphtheria along with the corresponding 95% Confidence Interval (CI) are presented.</description>
          <population>Evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningococcal C ≥ 1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="96.1" upper_limit="99.5"/>
                    <measurement group_id="O2" value="98.9" lower_limit="96.9" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diptheria ≥ 0.10 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" lower_limit="93.0" upper_limit="97.9"/>
                    <measurement group_id="O2" value="94.7" lower_limit="91.4" upper_limit="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diptheria ≥ 0.01 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Meningococcal C the difference in percentage between the two groups (13vPnC - 7vPnC) at ≥ 1:8 threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) greater than (&gt;) -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Diphtheria the difference in percentage between the two groups (13vPnC - 7vPnC) at ≥ 0.10 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Diphtheria the difference in percentage between the two groups (13vPnC - 7vPnC) at ≥ 0.01 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) of Meningococcal C in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series</title>
        <time_frame>One month after 2-doses of the infant series (5 months of age)</time_frame>
        <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 and 4 months. Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months (infant series). Participants received one single 0.5 mL dose of 13vPnC coadministered with MMR II at 12 months. Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months(toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 and 4 months. Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 6 months (infant series). Participants received one single 0.5 mL dose of 7vPnC coadministered with MMR II at 12 months. Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Meningococcal C in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series</title>
          <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191.22" lower_limit="167.72" upper_limit="218.02"/>
                    <measurement group_id="O2" value="266.19" lower_limit="234.86" upper_limit="301.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Meningococcal C the GMT ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for immune response induced by Meningitec was declared if the lower bound of the 2-sided, 95% CI for the GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentration (GMC) for Diphtheria in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series</title>
        <time_frame>One month after 2-doses of the infant series (5 months of age)</time_frame>
        <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 and 4 months. Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months (infant series). Participants received one single 0.5 mL dose of 13vPnC coadministered with MMR II at 12 months. Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 and 4 months. Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 6 months (infant series). Participants received one single 0.5 mL dose of 7vPnC coadministered with MMR II at 12 months. Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration (GMC) for Diphtheria in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series</title>
          <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" lower_limit="0.47" upper_limit="0.57"/>
                    <measurement group_id="O2" value="0.63" lower_limit="0.57" upper_limit="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Diphtheria the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for immune response induced by Meningitec was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-Specified Local Reactions</title>
        <description>Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig) (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>During the 4-day period after each dose</time_frame>
        <population>The safety population included all participants who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 months (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 months (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 4 months (infant series).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 4 months (infant series).</description>
          </group>
          <group group_id="O5">
            <title>13vPnC Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months (infant series).</description>
          </group>
          <group group_id="O6">
            <title>7vPnC Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 6 months (infant series).</description>
          </group>
          <group group_id="O7">
            <title>13vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).</description>
          </group>
          <group group_id="O8">
            <title>7vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Local Reactions</title>
          <description>Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig) (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>The safety population included all participants who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="306"/>
                <count group_id="O4" value="298"/>
                <count group_id="O5" value="301"/>
                <count group_id="O6" value="295"/>
                <count group_id="O7" value="293"/>
                <count group_id="O8" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness-Any (n=275,270,227,232,217,215,193,170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.5"/>
                    <measurement group_id="O2" value="43.3"/>
                    <measurement group_id="O3" value="45.4"/>
                    <measurement group_id="O4" value="46.6"/>
                    <measurement group_id="O5" value="47.9"/>
                    <measurement group_id="O6" value="41.9"/>
                    <measurement group_id="O7" value="64.2"/>
                    <measurement group_id="O8" value="64.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness-Sig (n=247,250,192,203,181,171,136,118</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="2.8"/>
                    <measurement group_id="O3" value="4.2"/>
                    <measurement group_id="O4" value="3.9"/>
                    <measurement group_id="O5" value="6.1"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="5.9"/>
                    <measurement group_id="O8" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Any (n=252,254,206,212,203,181,153,140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="14.2"/>
                    <measurement group_id="O3" value="28.2"/>
                    <measurement group_id="O4" value="23.1"/>
                    <measurement group_id="O5" value="27.6"/>
                    <measurement group_id="O6" value="28.2"/>
                    <measurement group_id="O7" value="33.3"/>
                    <measurement group_id="O8" value="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Mild (n=251,254,206,212,201,186,151,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="14.2"/>
                    <measurement group_id="O3" value="25.7"/>
                    <measurement group_id="O4" value="20.3"/>
                    <measurement group_id="O5" value="26.4"/>
                    <measurement group_id="O6" value="25.8"/>
                    <measurement group_id="O7" value="31.1"/>
                    <measurement group_id="O8" value="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Mod (n=247,248,191,201,180,173,136,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="1.6"/>
                    <measurement group_id="O3" value="5.8"/>
                    <measurement group_id="O4" value="4.5"/>
                    <measurement group_id="O5" value="5.6"/>
                    <measurement group_id="O6" value="4.0"/>
                    <measurement group_id="O7" value="11.8"/>
                    <measurement group_id="O8" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Severe(n=246,247,191,201,176,171,131,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Any (n=255,251,211,217,203,198,159,146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0"/>
                    <measurement group_id="O2" value="19.1"/>
                    <measurement group_id="O3" value="34.1"/>
                    <measurement group_id="O4" value="30.9"/>
                    <measurement group_id="O5" value="31.0"/>
                    <measurement group_id="O6" value="34.8"/>
                    <measurement group_id="O7" value="40.9"/>
                    <measurement group_id="O8" value="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Mild (n=254,251,210,215,203,195,157,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1"/>
                    <measurement group_id="O2" value="18.3"/>
                    <measurement group_id="O3" value="32.4"/>
                    <measurement group_id="O4" value="30.2"/>
                    <measurement group_id="O5" value="29.1"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="35.0"/>
                    <measurement group_id="O8" value="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Mod (n=247,247,192,203,177,175,137,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="3.1"/>
                    <measurement group_id="O4" value="2.5"/>
                    <measurement group_id="O5" value="4.5"/>
                    <measurement group_id="O6" value="5.1"/>
                    <measurement group_id="O7" value="13.1"/>
                    <measurement group_id="O8" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Severe (n=246,247,191,201,176,171,131,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-Specified Systemic Events</title>
        <description>Systemic events (fever [Fv] ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased [Decr] appetite, irritability, increased [Incr] sleep, decreased sleep, hives, use of medication [Med] to treat symptoms [sx], and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>During the 4-day period after each dose</time_frame>
        <population>The safety population included all subjects who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 months (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 months (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 4 months (infant series).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 4 months (infant series).</description>
          </group>
          <group group_id="O5">
            <title>13vPnC Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months (infant series).</description>
          </group>
          <group group_id="O6">
            <title>7vPnC Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 6 months (infant series).</description>
          </group>
          <group group_id="O7">
            <title>13vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).</description>
          </group>
          <group group_id="O8">
            <title>7vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Systemic Events</title>
          <description>Systemic events (fever [Fv] ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased [Decr] appetite, irritability, increased [Incr] sleep, decreased sleep, hives, use of medication [Med] to treat symptoms [sx], and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>The safety population included all subjects who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="306"/>
                <count group_id="O4" value="298"/>
                <count group_id="O5" value="301"/>
                <count group_id="O6" value="295"/>
                <count group_id="O7" value="293"/>
                <count group_id="O8" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fv≥38°C, ≤39°C (n=262,253,213,223,198,196,162,145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5"/>
                    <measurement group_id="O2" value="24.5"/>
                    <measurement group_id="O3" value="40.4"/>
                    <measurement group_id="O4" value="41.7"/>
                    <measurement group_id="O5" value="34.3"/>
                    <measurement group_id="O6" value="38.3"/>
                    <measurement group_id="O7" value="38.9"/>
                    <measurement group_id="O8" value="44.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fv&gt;39°C, ≤40°C (n=249,247,194,204,177,174,135,118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="2.6"/>
                    <measurement group_id="O4" value="2.5"/>
                    <measurement group_id="O5" value="5.6"/>
                    <measurement group_id="O6" value="5.2"/>
                    <measurement group_id="O7" value="8.1"/>
                    <measurement group_id="O8" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fv &gt;40°C (n=249,247,192,201,176,171,132,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.8"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decr appetite (n=269,258,226,229,219,204,174,147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8"/>
                    <measurement group_id="O2" value="36.8"/>
                    <measurement group_id="O3" value="45.1"/>
                    <measurement group_id="O4" value="44.5"/>
                    <measurement group_id="O5" value="47.0"/>
                    <measurement group_id="O6" value="42.6"/>
                    <measurement group_id="O7" value="53.4"/>
                    <measurement group_id="O8" value="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=276,267,234,244,229,221,183,170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4"/>
                    <measurement group_id="O2" value="42.7"/>
                    <measurement group_id="O3" value="64.5"/>
                    <measurement group_id="O4" value="61.5"/>
                    <measurement group_id="O5" value="57.2"/>
                    <measurement group_id="O6" value="58.8"/>
                    <measurement group_id="O7" value="61.7"/>
                    <measurement group_id="O8" value="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incr sleep (n=273,269,218,221,206,203,160,145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.5"/>
                    <measurement group_id="O2" value="51.3"/>
                    <measurement group_id="O3" value="46.8"/>
                    <measurement group_id="O4" value="41.6"/>
                    <measurement group_id="O5" value="33.5"/>
                    <measurement group_id="O6" value="34.5"/>
                    <measurement group_id="O7" value="39.4"/>
                    <measurement group_id="O8" value="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decr sleep (n=263,255,218,223,205,190,151,129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6"/>
                    <measurement group_id="O2" value="24.7"/>
                    <measurement group_id="O3" value="36.2"/>
                    <measurement group_id="O4" value="29.6"/>
                    <measurement group_id="O5" value="30.2"/>
                    <measurement group_id="O6" value="25.8"/>
                    <measurement group_id="O7" value="27.2"/>
                    <measurement group_id="O8" value="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Med-treat sx (n=267,256,232,243,216,209,176,163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6"/>
                    <measurement group_id="O2" value="46.9"/>
                    <measurement group_id="O3" value="60.3"/>
                    <measurement group_id="O4" value="61.3"/>
                    <measurement group_id="O5" value="55.6"/>
                    <measurement group_id="O6" value="55.5"/>
                    <measurement group_id="O7" value="59.7"/>
                    <measurement group_id="O8" value="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Med-prevent sx (n=269,258,231,237,222,211,178,159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1"/>
                    <measurement group_id="O2" value="47.7"/>
                    <measurement group_id="O3" value="58.4"/>
                    <measurement group_id="O4" value="58.6"/>
                    <measurement group_id="O5" value="56.3"/>
                    <measurement group_id="O6" value="53.6"/>
                    <measurement group_id="O7" value="59.6"/>
                    <measurement group_id="O8" value="61.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Group After the Second Dose and After the Third Dose of a 3-Dose Infant Series and After the Toddler Dose</title>
        <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes which are present in both 7vPnC and 13vPnC (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)</time_frame>
        <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate IgG antibody concentration to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 and 4 months (infant series).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC After Infant Series Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Group After the Second Dose and After the Third Dose of a 3-Dose Infant Series and After the Toddler Dose</title>
          <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes which are present in both 7vPnC and 13vPnC (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate IgG antibody concentration to the given serotype.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotype - Serotype 4 (n=269,269,241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" lower_limit="1.70" upper_limit="2.10"/>
                    <measurement group_id="O2" value="2.33" lower_limit="2.11" upper_limit="2.57"/>
                    <measurement group_id="O3" value="4.97" lower_limit="4.42" upper_limit="5.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype - Serotype 6B (n=267,267,228)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" lower_limit="0.37" upper_limit="0.47"/>
                    <measurement group_id="O2" value="3.88" lower_limit="3.41" upper_limit="4.41"/>
                    <measurement group_id="O3" value="11.88" lower_limit="10.57" upper_limit="13.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype - Serotype 9V (n=273,273,241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" lower_limit="1.34" upper_limit="1.66"/>
                    <measurement group_id="O2" value="1.71" lower_limit="1.56" upper_limit="1.86"/>
                    <measurement group_id="O3" value="3.44" lower_limit="3.12" upper_limit="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype - Serotype 14 (n=270,270,230)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.84" lower_limit="3.37" upper_limit="4.37"/>
                    <measurement group_id="O2" value="6.17" lower_limit="5.45" upper_limit="6.98"/>
                    <measurement group_id="O3" value="11.37" lower_limit="10.17" upper_limit="12.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype - Serotype 18C (n=267,267,239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" lower_limit="1.40" upper_limit="1.78"/>
                    <measurement group_id="O2" value="2.29" lower_limit="2.08" upper_limit="2.52"/>
                    <measurement group_id="O3" value="3.96" lower_limit="3.55" upper_limit="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype - Serotype 19F (n=270,270,231)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" lower_limit="2.53" upper_limit="3.21"/>
                    <measurement group_id="O2" value="2.64" lower_limit="2.42" upper_limit="2.89"/>
                    <measurement group_id="O3" value="8.04" lower_limit="7.07" upper_limit="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype - Serotype 23F (n=260,260,233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" lower_limit="0.47" upper_limit="0.62"/>
                    <measurement group_id="O2" value="2.15" lower_limit="1.89" upper_limit="2.45"/>
                    <measurement group_id="O3" value="5.07" lower_limit="4.50" upper_limit="5.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotype - Serotype 1 (n=268,268,235)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" lower_limit="1.70" upper_limit="2.13"/>
                    <measurement group_id="O2" value="3.04" lower_limit="2.73" upper_limit="3.38"/>
                    <measurement group_id="O3" value="4.79" lower_limit="4.21" upper_limit="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotype - Serotype 3 (n=267,267,243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" lower_limit="0.72" upper_limit="0.87"/>
                    <measurement group_id="O2" value="0.97" lower_limit="0.87" upper_limit="1.08"/>
                    <measurement group_id="O3" value="1.07" lower_limit="0.95" upper_limit="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotype - Serotype 5 (n=261,261,234)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.90" upper_limit="1.10"/>
                    <measurement group_id="O2" value="1.93" lower_limit="1.74" upper_limit="2.13"/>
                    <measurement group_id="O3" value="3.90" lower_limit="3.53" upper_limit="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotype - Serotype 6A (n=269,269,235)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" lower_limit="0.97" upper_limit="1.25"/>
                    <measurement group_id="O2" value="3.16" lower_limit="2.82" upper_limit="3.53"/>
                    <measurement group_id="O3" value="7.07" lower_limit="6.35" upper_limit="7.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotype - Serotype 7F (n=268,268,242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" lower_limit="1.69" upper_limit="2.02"/>
                    <measurement group_id="O2" value="4.03" lower_limit="3.70" upper_limit="4.40"/>
                    <measurement group_id="O3" value="5.78" lower_limit="5.13" upper_limit="6.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotype - Serotype 19A (n=267,267,226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" lower_limit="2.10" upper_limit="2.66"/>
                    <measurement group_id="O2" value="3.07" lower_limit="2.79" upper_limit="3.37"/>
                    <measurement group_id="O3" value="11.64" lower_limit="10.43" upper_limit="13.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 4, the Geometric Mean fold Rise (GMFR) were calculated using all participants with available data from both 13vPnC After Infant Series Dose 2 and 13vPnC After Infant Series Dose 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 6B the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>9.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.18</ci_lower_limit>
            <ci_upper_limit>10.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 6B, the GMFR were calculated using all participants with available data from both 13vPnC After Infant Series Dose 2 and 13vPnC After Infant Series Dose 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 14, the GMFR were calculated using all participants with available data from both 13vPnC After Infant Series Dose 2 and 13vPnC After Infant Series Dose 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>1.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.41</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 18C, the GMFR were calculated using all participants with available data from both 13vPnC After Infant Series Dose 2 and 13vPnC After Infant Series Dose 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>1.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.30</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 19F, the GMFR were calculated using all participants with available data from both 13vPnC After Infant Series Dose 2 and 13vPnC After Infant Series Dose 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 23F, the GMFR were calculated using all participants with available data from both 13vPnC After Infant Series Dose 2 and 13vPnC After Infant Series Dose 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>4.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.55</ci_lower_limit>
            <ci_upper_limit>4.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 1, the GMFR were calculated using all participants with available data from both 13vPnC After Infant Series Dose 2 and 13vPnC After Infant Series Dose 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>1.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.46</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 3, the GMFR were calculated using all participants with available data from both 13vPnC After Infant Series Dose 2 and 13vPnC After Infant Series Dose 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 5, the GMFR were calculated using all participants with available data from both 13vPnC After Infant Series Dose 2 and 13vPnC After Infant Series Dose 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>1.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.78</ci_lower_limit>
            <ci_upper_limit>2.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 6A, the GMFR were calculated using all participants with available data from both 13vPnC After Infant Series Dose 2 and 13vPnC After Infant Series Dose 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>2.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.58</ci_lower_limit>
            <ci_upper_limit>3.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 7F, the GMFR were calculated using all participants with available data from both 13vPnC After Infant Series Dose 2 and 13vPnC After Infant Series Dose 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>2.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.98</ci_lower_limit>
            <ci_upper_limit>2.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 19A, the GMFR were calculated using all participants with available data from both 13vPnC After Infant Series Dose 2 and 13vPnC After Infant Series Dose 3 blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.18</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Predefined Antibody Levels for Pertussis, Diphtheria, Tetanus, and Poliovirus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose</title>
        <description>Percentage of participants achieving predefined antibody threshold levels with the corresponding 95% CI for each concomitant antigen (pertussis antigens including Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA), and Pertactin (PRN); diphtheria; tetanus; and poliovirus types 1, 2, and 3) are presented.</description>
        <time_frame>One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)</time_frame>
        <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 6 months (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC After the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Predefined Antibody Levels for Pertussis, Diphtheria, Tetanus, and Poliovirus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose</title>
          <description>Percentage of participants achieving predefined antibody threshold levels with the corresponding 95% CI for each concomitant antigen (pertussis antigens including Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA), and Pertactin (PRN); diphtheria; tetanus; and poliovirus types 1, 2, and 3) are presented.</description>
          <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="286"/>
                <count group_id="O3" value="275"/>
                <count group_id="O4" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pertussis, PT ≥ 5.0 EU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.6" lower_limit="98.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="99.6" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis, PT (Infant ≥ 20; Toddler ≥ 11) EU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.2" lower_limit="89.7" upper_limit="95.8"/>
                    <measurement group_id="O2" value="95.1" lower_limit="91.9" upper_limit="97.3"/>
                    <measurement group_id="O3" value="94.9" lower_limit="91.6" upper_limit="97.2"/>
                    <measurement group_id="O4" value="96.3" lower_limit="93.3" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis, FHA ≥ 5.0 EU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis, FHA ≥ 7.82 EU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis, FHA (Infant ≥ 64; Toddler ≥ 99) EU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.9" lower_limit="90.5" upper_limit="96.3"/>
                    <measurement group_id="O2" value="95.1" lower_limit="91.9" upper_limit="97.3"/>
                    <measurement group_id="O3" value="94.5" lower_limit="91.1" upper_limit="96.9"/>
                    <measurement group_id="O4" value="95.1" lower_limit="91.8" upper_limit="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis, PRN ≥ 5 EU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis, PRN (Infant ≥ 39; Toddler ≥ 69) EU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" lower_limit="91.3" upper_limit="96.8"/>
                    <measurement group_id="O2" value="95.1" lower_limit="91.9" upper_limit="97.3"/>
                    <measurement group_id="O3" value="93.5" lower_limit="89.9" upper_limit="96.1"/>
                    <measurement group_id="O4" value="95.2" lower_limit="91.9" upper_limit="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diptheria ≥ 0.10 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="97.5" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.2" lower_limit="97.2" upper_limit="99.9"/>
                    <measurement group_id="O4" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diptheria ≥ 0.01 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus ≥ 0.10 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" lower_limit="96.3" upper_limit="99.6"/>
                    <measurement group_id="O2" value="98.2" lower_limit="95.8" upper_limit="99.4"/>
                    <measurement group_id="O3" value="98.6" lower_limit="95.9" upper_limit="99.7"/>
                    <measurement group_id="O4" value="97.8" lower_limit="94.9" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus ≥ 0.01 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.3" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus, Type 1 ≥ 1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus, Type 2 ≥ 1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.3" lower_limit="97.5" upper_limit="99.9"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O4" value="99.6" lower_limit="97.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus, Type 3 ≥ 1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.6" lower_limit="98.0" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis, PT the difference in percentage between the two groups (13vPnC - 7vPnC) at 5.0 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis, PT the difference in percentage between the two groups (13vPnC - 7vPnC) at 20 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.0</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis, FHA the difference in percentage between the two groups (13vPnC - 7vPnC) at 5.0 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis, FHA the difference in percentage between the two groups (13vPnC - 7vPnC) at 7.82 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis, FHA the difference in percentage between the two groups (13vPnC - 7vPnC) at 64 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.2</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis, PRN the difference in percentage between the two groups (13vPnC - 7vPnC) at 5 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis, PRN the difference in percentage between the two groups (13vPnC - 7vPnC) at 39 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis, PT the difference in percentage between the two groups (13vPnC - 7vPnC) at 5.0 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis, PT the difference in percentage between the two groups (13vPnC - 7vPnC) at 11 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.1</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis, FHA the difference in percentage between the two groups (13vPnC - 7vPnC) at 5.0 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis, FHA the difference in percentage between the two groups (13vPnC - 7vPnC) at 7.82 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis, FHA the difference in percentage between the two groups (13vPnC - 7vPnC) at 99 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis, PRN the difference in percentage between the two groups (13vPnC - 7vPnC) at 5 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis, PRN the difference in percentage between the two groups (13vPnC - 7vPnC) at 69 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Diphtheria the difference in percentage between the two groups (13vPnC - 7vPnC) at 0.10 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Diphtheria the difference in percentage between the two groups (13vPnC - 7vPnC) at 0.01 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Diphtheria the difference in percentage between the two groups (13vPnC - 7vPnC) at 0.10 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Diphtheria the difference in percentage between the two groups (13vPnC - 7vPnC) at 0.01 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Tetanus the difference in percentage between the two groups (13vPnC - 7vPnC) at 0.10 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Tetanus the difference in percentage between the two groups (13vPnC - 7vPnC) at 0.01 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Tetanus the difference in percentage between the two groups (13vPnC - 7vPnC) at 0.10 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Tetanus the difference in percentage between the two groups (13vPnC - 7vPnC) at 0.01 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Poliovirus Type 1 the difference in percentage between the two groups (13vPnC - 7vPnC) at 1:8 threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Poliovirus Type 2 the difference in percentage between the two groups (13vPnC - 7vPnC) at 1:8 threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Poliovirus Type 3 the difference in percentage between the two groups (13vPnC - 7vPnC) at 1:8 threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Poliovirus Type 1 the difference in percentage between the two groups (13vPnC - 7vPnC) at 1:8 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Poliovirus Type 2 the difference in percentage between the two groups (13vPnC - 7vPnC) at 1:8 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Poliovirus Type 3 the difference in percentage between the two groups (13vPnC - 7vPnC) at 1:8 EU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMT) for Poliovirus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose</title>
        <time_frame>One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)</time_frame>
        <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After Infant Series Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 6 months (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC Afte the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMT) for Poliovirus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose</title>
          <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="286"/>
                <count group_id="O3" value="275"/>
                <count group_id="O4" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Poliovirus Type 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="436.98" lower_limit="378.21" upper_limit="504.88"/>
                    <measurement group_id="O2" value="436.15" lower_limit="378.17" upper_limit="503.02"/>
                    <measurement group_id="O3" value="1057.40" lower_limit="939.06" upper_limit="1190.70"/>
                    <measurement group_id="O4" value="1286.70" lower_limit="1131.00" upper_limit="1463.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus Type 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266.34" lower_limit="227.84" upper_limit="311.36"/>
                    <measurement group_id="O2" value="281.85" lower_limit="240.04" upper_limit="330.94"/>
                    <measurement group_id="O3" value="1032.30" lower_limit="912.96" upper_limit="1167.10"/>
                    <measurement group_id="O4" value="1141.10" lower_limit="992.96" upper_limit="1311.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus Type 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="897.67" lower_limit="766.30" upper_limit="1051.60"/>
                    <measurement group_id="O2" value="943.95" lower_limit="806.71" upper_limit="1104.50"/>
                    <measurement group_id="O3" value="2571.10" lower_limit="2249.40" upper_limit="2938.90"/>
                    <measurement group_id="O4" value="2410.80" lower_limit="2106.70" upper_limit="2758.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Poliovirus Type 1 the GMT ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Poliovirus Type 2 the GMT ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Poliovirus Type 3 the GMT ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For Poliovirus Type 1 the GMT ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Poliovirus Type 2 the GMT ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Poliovirus Type 3 the GMT ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMT ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentrations (GMC) for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose</title>
        <time_frame>One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)</time_frame>
        <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After Infant Series Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 6 months (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC Afte the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentrations (GMC) for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose</title>
          <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="286"/>
                <count group_id="O3" value="275"/>
                <count group_id="O4" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" lower_limit="1.08" upper_limit="1.30"/>
                    <measurement group_id="O2" value="1.40" lower_limit="1.28" upper_limit="1.53"/>
                    <measurement group_id="O3" value="3.00" lower_limit="2.65" upper_limit="3.40"/>
                    <measurement group_id="O4" value="3.51" lower_limit="3.08" upper_limit="3.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="0.80" upper_limit="1.01"/>
                    <measurement group_id="O2" value="0.87" lower_limit="0.79" upper_limit="0.97"/>
                    <measurement group_id="O3" value="1.63" lower_limit="1.38" upper_limit="1.91"/>
                    <measurement group_id="O4" value="1.45" lower_limit="1.24" upper_limit="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For diphtheria toxoid the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Tetanus the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For diphtheria toxoid the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Tetanus the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentrations (GMC) for Pertussis in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose</title>
        <description>GMCs with the corresponding 95% CI for each concomitant antigen pertussis antigens (PT, FHA, PRN, and FIM) as measured by EU/mL are presented.</description>
        <time_frame>One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)</time_frame>
        <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After Infant Series Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 6 months (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC Afte the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentrations (GMC) for Pertussis in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose</title>
          <description>GMCs with the corresponding 95% CI for each concomitant antigen pertussis antigens (PT, FHA, PRN, and FIM) as measured by EU/mL are presented.</description>
          <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="286"/>
                <count group_id="O3" value="275"/>
                <count group_id="O4" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pertussis PT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.51" lower_limit="47.94" upper_limit="55.34"/>
                    <measurement group_id="O2" value="50.13" lower_limit="46.80" upper_limit="53.70"/>
                    <measurement group_id="O3" value="36.13" lower_limit="32.84" upper_limit="39.74"/>
                    <measurement group_id="O4" value="36.01" lower_limit="32.94" upper_limit="39.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis FHA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.04" lower_limit="165.34" upper_limit="193.87"/>
                    <measurement group_id="O2" value="166.77" lower_limit="155.20" upper_limit="179.20"/>
                    <measurement group_id="O3" value="347.96" lower_limit="316.46" upper_limit="382.59"/>
                    <measurement group_id="O4" value="345.89" lower_limit="315.14" upper_limit="379.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis PRN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.39" lower_limit="129.66" upper_limit="154.17"/>
                    <measurement group_id="O2" value="135.06" lower_limit="123.56" upper_limit="147.63"/>
                    <measurement group_id="O3" value="232.96" lower_limit="211.42" upper_limit="256.69"/>
                    <measurement group_id="O4" value="261.58" lower_limit="237.29" upper_limit="288.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis PT the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis FHA the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis PRN the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis PT the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis FHA the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis PRN the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Antibody Level ≥ 0.35 Microgram Per Milliliter (μg/mL) in 13vPnC Group After the Second Dose and After the Third Dose of a 3-Dose Infant Series and After the Toddler Dose</title>
        <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes, present in both 13vPnC and 7vPnC (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)</time_frame>
        <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 4 months (infant series).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC After Infant Series Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Antibody Level ≥ 0.35 Microgram Per Milliliter (μg/mL) in 13vPnC Group After the Second Dose and After the Third Dose of a 3-Dose Infant Series and After the Toddler Dose</title>
          <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes, present in both 13vPnC and 7vPnC (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotype - Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" lower_limit="93.7" upper_limit="98.5"/>
                    <measurement group_id="O2" value="98.9" lower_limit="96.8" upper_limit="99.8"/>
                    <measurement group_id="O3" value="99.2" lower_limit="97.0" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype - Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" lower_limit="51.1" upper_limit="63.3"/>
                    <measurement group_id="O2" value="98.5" lower_limit="96.2" upper_limit="99.6"/>
                    <measurement group_id="O3" value="99.6" lower_limit="97.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype - Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.9" lower_limit="88.1" upper_limit="94.9"/>
                    <measurement group_id="O2" value="99.3" lower_limit="97.4" upper_limit="99.9"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype - Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="96.3" upper_limit="99.6"/>
                    <measurement group_id="O2" value="97.4" lower_limit="94.7" upper_limit="99.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype - Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.8" lower_limit="87.8" upper_limit="94.8"/>
                    <measurement group_id="O2" value="98.1" lower_limit="95.7" upper_limit="99.4"/>
                    <measurement group_id="O3" value="99.6" lower_limit="97.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype - Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="95.2" upper_limit="99.2"/>
                    <measurement group_id="O2" value="99.3" lower_limit="97.3" upper_limit="99.9"/>
                    <measurement group_id="O3" value="99.6" lower_limit="97.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype - Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1" lower_limit="62.0" upper_limit="73.7"/>
                    <measurement group_id="O2" value="94.6" lower_limit="91.1" upper_limit="97.0"/>
                    <measurement group_id="O3" value="99.1" lower_limit="96.9" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotype - Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" lower_limit="93.2" upper_limit="98.2"/>
                    <measurement group_id="O2" value="99.3" lower_limit="97.3" upper_limit="99.9"/>
                    <measurement group_id="O3" value="98.7" lower_limit="96.3" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotype - Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.0" lower_limit="83.5" upper_limit="91.7"/>
                    <measurement group_id="O2" value="90.3" lower_limit="86.1" upper_limit="93.5"/>
                    <measurement group_id="O3" value="92.2" lower_limit="88.1" upper_limit="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotype - Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.4" lower_limit="82.7" upper_limit="91.1"/>
                    <measurement group_id="O2" value="97.3" lower_limit="94.6" upper_limit="98.9"/>
                    <measurement group_id="O3" value="99.1" lower_limit="96.9" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotype - Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.4" lower_limit="79.5" upper_limit="88.5"/>
                    <measurement group_id="O2" value="97.4" lower_limit="94.7" upper_limit="98.9"/>
                    <measurement group_id="O3" value="99.1" lower_limit="97.0" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotype - Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="96.2" upper_limit="99.6"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="98.8" lower_limit="96.4" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotype - Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="95.7" upper_limit="99.4"/>
                    <measurement group_id="O2" value="99.6" lower_limit="97.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 4, the difference in percentages between the two groups (13vPnC After Infant Series Dose 2 - 13vPnC After Infant Series Dose 3) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 6B, the difference in percentages between the two groups (13vPnC After Infant Series Dose 2 - 13vPnC After Infant Series Dose 3) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>41.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>34.9</ci_lower_limit>
            <ci_upper_limit>46.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 9V, the difference in percentages between the two groups (13vPnC After Infant Series Dose 2 - 13vPnC After Infant Series Dose 3) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>7.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.1</ci_lower_limit>
            <ci_upper_limit>10.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 14, the difference in percentages between the two groups (13vPnC After Infant Series Dose 2 - 13vPnC After Infant Series Dose 3) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 18C, the difference in percentages between the two groups (13vPnC After Infant Series Dose 2 - 13vPnC After Infant Series Dose 3) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>6.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.1</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 19F, the difference in percentages between the two groups (13vPnC After Infant Series Dose 2 - 13vPnC After Infant Series Dose 3) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 23F, the difference in percentages between the two groups (13vPnC After Infant Series Dose 2 - 13vPnC After Infant Series Dose 3) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>26.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>20.7</ci_lower_limit>
            <ci_upper_limit>31.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 1, the difference in percentages between the two groups (13vPnC After Infant Series Dose 2 - 13vPnC After Infant Series Dose 3) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>5.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 3, the difference in percentages between the two groups (13vPnC After Infant Series Dose 2 - 13vPnC After Infant Series Dose 3) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>6.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 5, the difference in percentages between the two groups (13vPnC After Infant Series Dose 2 - 13vPnC After Infant Series Dose 3) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>10.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.9</ci_lower_limit>
            <ci_upper_limit>13.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 6A, the difference in percentages between the two groups (13vPnC After Infant Series Dose 2 - 13vPnC After Infant Series Dose 3) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>13.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.6</ci_lower_limit>
            <ci_upper_limit>17.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 7F, the difference in percentages between the two groups (13vPnC After Infant Series Dose 2 - 13vPnC After Infant Series Dose 3) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 19A, the difference in percentages between the two groups (13vPnC After Infant Series Dose 2 - 13vPnC After Infant Series Dose 3) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>13vPnC Infant Series</title>
          <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 and 4 months, assessment was done approximately one month after dose 2 at 5 months of age.</description>
        </group>
        <group group_id="E2">
          <title>7vPnC Infant Series</title>
          <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a combination vaccine Infanrix hexa and Meningitec at 2 and 4 months, assessment was done approximately one month after dose 2 at 5 months of age.</description>
        </group>
        <group group_id="E3">
          <title>13vPnC Post-Infant Series</title>
          <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix hexa at 6 months (infant series), assessment was done approximately one month after dose 3 at 7 months of age.</description>
        </group>
        <group group_id="E4">
          <title>7vPnC Post-Infant Series</title>
          <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix hexa at 6 months, assessment was done approximately one month after dose 3 at 7 months of age.</description>
        </group>
        <group group_id="E5">
          <title>13vPnC Toddler Series</title>
          <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with MMR II at 12 months. Participants received one single 0.5 mL dose of 13vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose). Assessment was done approximately one month after toddler dose at 16 months of age.</description>
        </group>
        <group group_id="E6">
          <title>7vPnC Toddler Series</title>
          <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with MMR II at 12 months. Participants received one single 0.5 mL dose of 7vPnC coadministered with Infanrix-IPV+Hib and Meningitec at 15 months (toddler dose). Assessment was done approximately one month after toddler dose at 16 months of age.</description>
        </group>
        <group group_id="E7">
          <title>13vPnC 6-Month Follow-up</title>
          <description>Assessment was done approximately 6 months after 13vPnC toddler dose at 21 months of age.</description>
        </group>
        <group group_id="E8">
          <title>7vPnC 6-Month Follow-up</title>
          <description>Assessment was done approximately 6 months after 7vPnC toddler dose at 21 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Local Reactions</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Scaphocephaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Sudden infant death syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Fontanelle bulging</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (moderate)</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="248"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="136"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="124"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Local Reactions</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="156" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="124" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="110" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hip dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Double ureter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Hypospadias</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Strabismus congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Conjuctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever ≥38 degrees C but ≤39 degrees C</description>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="63" subjects_at_risk="162"/>
                <counts group_id="E6" subjects_affected="65" subjects_at_risk="145"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever ≥38 degrees C but ≤39 degrees C</description>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever ≥38 degrees C but ≤39 degrees C</description>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt;39 degrees C but ≤40 degrees C</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt;39 degrees C but ≤40 degrees C</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever &gt;39 degrees C but ≤40 degrees C</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt;40 degrees C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt;40 degrees C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever &gt;40 degrees C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="258"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="93" subjects_at_risk="174"/>
                <counts group_id="E6" subjects_affected="70" subjects_at_risk="147"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Irritability</description>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="276"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="113" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="105" subjects_at_risk="170"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Irritability</description>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="150" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Irritability</description>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="130" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Increased sleep</description>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="63" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="51" subjects_at_risk="145"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Increased sleep</description>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Increased sleep</description>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="41" subjects_at_risk="151"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="129"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Coxsackie viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Dacryocystitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Viral skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Lactose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pyelocaliectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Penis disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Testicular retraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Genital rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Tenderness (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="124" subjects_at_risk="193"/>
                <counts group_id="E6" subjects_affected="110" subjects_at_risk="170"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Tenderness (any)</description>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness (Any)</sub_title>
                <description>Infant Series Dose 3; Tenderness (any)</description>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness (Significant)</sub_title>
                <description>Infant Series Dose 1 and Toddler Dose; Tenderness (significant)=present and interfered with limb movement.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness (Significant)</sub_title>
                <description>Infant Series Dose 2; Tenderness (significant)</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness (Significant)</sub_title>
                <description>Infant Series Dose 3; Tenderness (significant)</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="51" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="140"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (any)</description>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (any)</description>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Mild)</sub_title>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (mild)=0.5 centimeters (cm) to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="251"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="151"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (mild)</description>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (mild)</description>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (moderate)=2.5 cm to 7.0 cm.</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="124"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (moderate)</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (moderate)</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="65" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="60" subjects_at_risk="146"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (any)</description>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (any)</description>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (mild)=0.5 cm to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="55" subjects_at_risk="157"/>
                <counts group_id="E6" subjects_affected="53" subjects_at_risk="141"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (mild)</description>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (mild)</description>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (moderate)=2.5 cm to 7.0 cm.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (moderate)</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (moderate)</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="175"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Exposure to communicable disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>U. S. Contact Center</name_or_title>
      <organization>Wyeth</organization>
      <email>clintrialresults@wyeth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

